Medicinal composition for preventing and treating atherosclerosis

A technology of atherosclerosis and composition, applied in the field of pharmaceutical composition for preventing and treating atherosclerosis

Active Publication Date: 2011-07-20
SUN YAT SEN UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the combined use of this drug with statins

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for preventing and treating atherosclerosis
  • Medicinal composition for preventing and treating atherosclerosis
  • Medicinal composition for preventing and treating atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Extraction, separation and purification of tanshinone II-A

[0028] Dried Salvia miltiorrhiza 1 kg, extracted with 95% ethanol three times (1000 ml each time), 24 hours each time, concentrated the extract to 500 ml under reduced pressure, then added 500 ml water, and divided it four times with 1000 ml chloroform Extraction, concentration of the extract under reduced pressure, separation by column chromatography, the silica gel is 100-200 mesh, the eluent is a mixed solution of petroleum ether / ethyl acetate containing 1%-10% ethyl acetate, and gradient elution is carried out. About 1.8 g of tanshinone II-A with a purity of 98% can be obtained.

Embodiment 2

[0029] Example 2 Effect of combined administration of Tanshinone II-A and atorvastatin on blood lipids in ApoE knockout mice

[0030] 5-week-old male ApoE knockout mice (ApoE - / - ) was purchased from the Department of Experimental Animals, Peking University Health Science Center (introduced from the Jackson Laboratory of the United States, animal certificate number: SCXK (Beijing) 2006-0008). C57BL / 6J male mice of the same strain and the same week of age were purchased from the Experimental Animal Center of Southern Medical University (5 weeks old, SPF grade, animal certificate number: SCXK (Guangdong) 2006-0015). After the experimental animals were bought back, they were kept in the SPF environment of the Experimental Center of the School of Public Health, Sun Yat-sen University (temperature 25±0.5 degrees, humidity 60%-70%, light 12h / dark 12h), and adaptive feeding for 1 week, and the next week (6 weeks) Start feeding high-fat feed (basic feed + 10% lard + 1.25% cholesterol...

Embodiment 3

[0035] Example 3 Effect of combined administration of Tanshinone II-A and atorvastatin on the area of ​​aortic sinus plaque in ApoE knockout mice

[0036] The experimental grouping is the same as in Example 2. The perfused heart was removed, rinsed with PBS to remove residual blood, and cut with a blade parallel to the line where the left and right atrial appendages were located or perpendicular to the aortic root, leaving the upper half of the heart tissue (with a 1 mm aortic root). arteries), coated in a mold containing OCT (Tissue-Tek), immediately frozen in liquid nitrogen and stored in a -80°C refrigerator. Frozen slices were frozen on a Leica cryostat, and the slices were continuously sliced ​​until the three valves of the aortic sinus completely appeared, and the slices were collected with a thickness of 8 μm, and a slice was attached at an interval of 50 μm. ) lay out 6 slices. After cutting the slices, store the slices at -80°C. Sections were stained with Oil Red O...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicinal composition for preventing and treating atherosclerosis. The medicinal composition comprises tanshinone II-A and atorvastatin, wherein the weight part ratio of the tanshinone II-A to the atorvastatin is preferably 10:(2-10); the tanshinone II-A is combined with the atorvastatin as a statin drug for use, so that the curative effect of high dosage of the tanshinone II-A or the atorvastatin can be achieved by a small dosage of the combined tanshinone II-A and atorvastatin, and the synergistic effect is obvious after drug combination; thus the areas of a lipid core and plaques can be obviously reduced, macrophage infiltration is reduced, collagen content in the plaques is increased, conditions of activation of NF-kB (Nuclear Factor-kappa B) are reduced, production of active oxygen in arterial plaques is inhibited, and the like. The medicinal composition for preventing and treating atherosclerosis has broad application prospect.

Description

technical field [0001] The invention relates to a pharmaceutical composition for preventing and treating atherosclerosis. Background technique [0002] Atherosclerosis (Atherosclerosis, As) is a common type of cardiovascular disease. With the improvement of people's living standards and changes in lifestyle, the incidence of cardiovascular diseases, especially coronary heart disease caused by As, is increasing year by year. At present, cardiovascular and cerebrovascular diseases caused by As have become one of the most important diseases that threaten human health and life. A large number of research results have shown that AS is not only a lipid storage disease, but also an inflammatory and immune disease. Inflammation plays an important role in the formation and development of As plaques. The formation, rupture and subsequent thrombosis of As plaques are the main pathological basis for clinical acute cardiovascular events (unstable angina, stroke, sudden death, etc.) (20...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61K31/40A61P9/10
CPCY02A50/30
Inventor 刘培庆古练权徐索文
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap